From the publishers of JADPRO

CAR T-Cell Therapy Resource Center

Advertisement

Monitoring of Circulating Tumor DNA Improves Early Relapse Detection After Axicabtagene Ciloleucel Infusion in Large B-Cell Lymphoma: Results of a Prospective Multi-Institutional Trial

Last Updated: Tuesday, October 19, 2021

This prospective multicenter study found that noninvasive circulating tumor DNA assessments can risk stratify and predict outcomes of patients undergoing axicabtagene ciloleucel for the treatment of large B-cell lymphoma.

Journal of Clinical Oncology
Advertisement
News & Literature Highlights
Advertisement
Advertisement